Physician profile
George E Miguel
NPI 1174591010
$2,494.55
in general payments reported to CMS, 2019-2025
21 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $791 · 2021: $421 · 2022: $191 · 2023: $121 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $463.97 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $330.79 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $329.28 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $225.06 | 2019-2022 | |
| Abiomed | $217.41 | 2025 | |
| Vanda Pharmaceuticals INC. | $189.87 | 2020-2022 | |
| Abbvie INC. | $137.03 | 2021-2023 | |
| Lundbeck LLC | $130.50 | 2019-2021 | |
| Alkermes, INC. | $97.17 | 2019 | |
| Pfizer INC. | $90.76 | 2019 | |
| Allergan, INC. | $56.78 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $53.93 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.55 | 2020-2021 | |
| Shire North American Group INC | $32.71 | 2019 | |
| Merck Sharp & Dohme LLC | $22.11 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $18.19 | 2020 | |
| Neurocrine Biosciences, INC. | $15.17 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.79 | 2019 | |
| Tepha INC | $12.30 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.84 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Miguel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.